Medical Devices industry M&A deals in April 2021
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
X

Medical Devices industry M&A deals total $9.2bn globally in April 2021

24 May 2021

Total medical devices industry M&A deals worth $9.2bn were announced globally in April 2021, led by $5bn merger of CA Healthcare Acquisition and LumiraDx, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the image source into your website to display the chart.

The value marked an increase of 137.6% over the previous month of $3.86bn and a rise of 17.3% when compared with the last 12-month average, which stood at $7.82bn.

Comparing M&A deals value in different regions of the globe, North America held the top position, with total announced deals in the period worth $7.41bn. At the country level, the US topped the list in terms of deal value at $7.41bn.

In terms of volumes, North America emerged as the top region for medical devices industry M&A deals globally, followed by Europe and then Asia-Pacific.

The top country in terms of M&A deals activity in April 2021 was the US with 23 deals, followed by the Germany with six and the UK with four.

In 2021, as of April, medical devices M&A deals worth $38.99bn were announced globally, marking an increase of 1259.1% year on year.

medical devices industry M&A deals in April 2021: Top deals

The top five M&A deals accounted for 92.05% of the overall value during April 2021.

The combined value of the top five medical devices M&A deals stood at $8.44bn, against the overall value of $9.2bn recorded for the month.

The top five medical devices industry M&A deals of April 2021 tracked by GlobalData were:

1) The $5bn merger of CA Healthcare Acquisition and LumiraDx

2) The $1.8bn acquisition of Luminex by DiaSorin

3) Hologic’s $795m acquisition of Mobidiag

4) The $626.41m acquisition of Pacific Radiology by Infratil

5) AddLife’s acquisition of Vision Ophthalmology Group for $216.53m.

Verdict deals analysis methodology

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.

More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.